
    
      This was a prospective, randomized study conducted from 2004 to 2006 at a single tertiary
      urban teaching University Urological Department regarding sixty-four patients with high-risk
      superficial bladder cancer (pT1, and/or G3 and/or CIS), who were assigned to interventions
      (gemcitabine or BCG) by using random allocation 1:1. Group A, 32 patients, were treated
      weekly (6 weekly instillations) with BCG dose 5 x 108 CFU and then maintenance therapy at
      3-6-12-18-24-30-36 months; Group B, 32 patients, received gemcitabine 2 gr/instillation on a
      weekly basis (6 weekly instillations), followed by maintenance therapy at 3-6-12-18-24-30-36
      months.
    
  